A growing arsenal of non-insulin diabetes medications is expanding therapeutic options beyond traditional insulin therapy. GLP-1 receptor agonists and SGLT2 inhibitors have demonstrated significant benefits in glycemic control while reducing cardiovascular risks. DPP-4 inhibitors offer a convenient oral alternative, particularly for patients seeking weight-neutral treatments. Recent advancements include combination therapies that target multiple metabolic pathways simultaneously, enhancing efficacy while minimizing side effects. Additionally, bile acid sequestrants, dopamine agonists, and amylin analogs provide novel mechanisms for improving insulin sensitivity. With continued research into incretin-based therapies and dual-agonist formulations, non-insulin medications are playing a crucial role in personalized diabetes management.
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : Important roles and mechanisms of novel calcium signaling in diabetes-induced vascular dementia
Yong Xiao Wang, Albany Medical College, United States
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters?
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : Diabetes reduction (pre-diabetes and type 2) with integrative medicine
F Buck Willis, Belize Bible College, Belize
Title : The menopausal mind: Reframing female senescence as a neuroendocrine disorder with root cause management strategies
Amy Gutman, AdventHealth; Tough Love MD, United States
Title : Bridging the gap: Coaching patients on GLP-1s for sustainable outcomes beyond the prescription
Keith Hersey, Master Your GLP-1, United States